| UHC Surest Medical and Drug | Intravenous Iron Replacement Therapy (Feraheme®, Injectafer®, & Monoferric®) - Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Kisunla™ (Donanemab-Azbt) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Manipulation Under Anesthesia – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Minimally Invasive Spine Surgery Procedures – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) - Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Skin and Soft Tissue Substitutes – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Tepezza® (Teprotumumab-Trbw) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Tezspire® (Tezepelumab-Ekko) – Commercial Medical Benefit Drug Policy | 2026-02-01 |
| UHC Surest Medical and Drug | Total Artificial Disc Replacement for the Spine – Commercial and Individual Exchange Medical Policy | 2026-02-01 |
| Medicare NCD | NCD 110.18 - Aprepitant for Chemotherapy-Induced Emesis | 2026-02-01 |